Eight month delay to diabetes drug

The replacement diabetes drug to Takeda blockbuster drug Actos could face an eight month delay, as the Food and Drug Administration debate approval. The FDA will respond to an application by Takeda Pharmaceutical Co. to sell Alogliptin.
The experimental medication will be decided on by late June 2009, with the final deadline of October 27th. Takeda, who are based in Osaka, Japa, released a statement detailing the decision. Actos, which is the best selling diabetes drug in the world, will lose patent protection in 2011 and may then experience a decline in sales .
A spokeswoman for Takeda, Ayako Iwamuro, was reported in the diabetes news as commenting: “It’s an FDA matter. They didn’t ask us for any additional data.”

To Top